Catalog No.
RHF65601
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
LAGE2B, CTAG1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CTAG1A, L antigen family member 2, Cancer/testis antigen 1, LAGE2A, ESO1, CTAG, LAGE-2, LAGE2, CT6.1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P78358
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1578
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies., PMID:40054461
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer., PMID:39900126
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer., PMID:39576208
NY-ESO-1 antigen: A promising frontier in cancer immunotherapy., PMID:39275923
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer., PMID:38964205
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer., PMID:38309723
Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients., PMID:36527482
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy., PMID:34933966
Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma., PMID:34728178
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients., PMID:33751208
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer., PMID:33458968
Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1., PMID:33237767
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells., PMID:32737142
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma., PMID:32317292
Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine., PMID:32088020
Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53., PMID:32083570
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors., PMID:31980914
Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early Diagnosis of Lung Cancer., PMID:31924693
Expression of tumor-associated antigens in breast cancer subtypes., PMID:31869767
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma., PMID:31699709
Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy., PMID:31527633
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab., PMID:31409922
Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer., PMID:31309741
Discovery and Validation of a Serologic Autoantibody Panel for Early Diagnosis of Esophageal Squamous Cell Carcinoma., PMID:31239266
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1., PMID:31069460
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer., PMID:30736848
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation., PMID:29473162
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1., PMID:29306769
[Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide]., PMID:29045966
Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status., PMID:28716148
[Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas]., PMID:28631119
Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group., PMID:27793776
Inducible expression of cancer-testis antigens in human prostate cancer., PMID:27769045
Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer., PMID:27140836
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer., PMID:27103177
Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination., PMID:26888315
Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis., PMID:26823828
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer., PMID:26324743
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer., PMID:26191258
Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells., PMID:26185907
Plasma Autoantibodies Associated with Basal-like Breast Cancers., PMID:26070530
NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers., PMID:25906289
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma., PMID:25633712
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors., PMID:25412843
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus., PMID:25081390
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation., PMID:25078248
Cancer vaccine shows benefit in solid tumors., PMID:25002633
Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates., PMID:24795353
Update on vaccines for high-risk melanoma., PMID:24788575
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial., PMID:24777970
For research use only. Not for human or drug use.
